Avatrombopag
RxNorm 2045726
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2045726 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: avatrombopag.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
INPrescribable
Ingredient (IN):
Avatrombopag
(Atom ID: 10272857)
PTPrescribable
Designated preferred name (PT):
Avatrombopag
(Atom ID: 10797331)
FNPrescribable
Full form of descriptor (FN):
Avatrombopag (substance)
(Atom ID: 10797332)
PTPrescribable
Designated preferred name (PT):
Avatrombopag-containing product
(Atom ID: 10797335)
FNPrescribable
Full form of descriptor (FN):
Product containing avatrombopag (medicinal product)
(Atom ID: 10810011)
Patient Education
Avatrombopag
Avatrombopag is used to treat thrombocytopenia (a low number of platelets [type of blood cell needed for blood clotting]) in people with chronic (ongoing) liver disease who are scheduled to have a medical or dental procedure to help prevent bleeding complications. It is also used to treat thrombocytopenia in people with chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood) who were not helped with another treatment. Avatrombopag is in a class of medications called thrombopoietin (TPO) receptor agonists. It works by causing the body to produce more platelets.
[Learn More]
* Please review the disclaimer below.